Neurological Biomarkers Market to Grow with a CAGR of 8.19% through 2028
Increasing Prevalence of Neurological Disorders and increase in the
aging population is expected to drive the Global Neurological Biomarkers Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Neurological
Biomarkers Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Neurological Biomarkers
Market stood at USD 7.42 billion in 2022 and is anticipated to grow with a CAGR
of 8.19% in the forecast period, 2024-2028. The awareness among individuals
regarding Neurological Biomarkers has led to favorable market conditions for
the global Neurological Biomarkers market. Several factors contribute to the
growth of various Neurological Biomarkers products. The increasing prevalence of neurological disorders
such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy,
and stroke is a significant catalyst. As these conditions become more
widespread, the demand for precise diagnostic and monitoring tools, including
biomarkers, experiences growth. The expanding global aging population is
another pivotal driver, as numerous neurological disorders are more prevalent
among older individuals. As the elderly demographic continues to grow, the
necessity for biomarkers to enable early detection and management of
age-related neurological conditions rises. Furthermore, ongoing advancements in
diagnostic technologies, especially in the realms of neuroimaging, genomics,
proteomics, and metabolomics, have brought about a revolutionary shift in
biomarker discovery and validation. These breakthroughs empower the development
of biomarkers that are increasingly sensitive and specific.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Neurological Biomarkers Market”
Technological advancements have ushered in the era of
personalized medicine, and the neurological biomarkers market is no exception.
With the help of genomic and molecular profiling, healthcare providers can
tailor treatment plans to individual patients based on their unique genetic
makeup and biomarker profiles. This level of personalization not only enhances
treatment efficacy but also reduces the risk of adverse effects. Patients receive
therapies that are more likely to work for them, leading to better clinical
outcomes and increased patient satisfaction. As a result, the adoption of
biomarker-driven personalized medicine is on the rise, driving market
expansion.
In August 2023, PerkinElmer launched the new Chemagic
Prime 3 DNA and RNA extraction system. This system is designed to provide fast,
high-quality extraction of DNA and RNA from a variety of sample types,
including blood, tissue, and saliva. The Chemagic Prime 3 system is ideal for a
variety of applications, including molecular diagnostics, clinical research,
and agricultural biotechnology. Increasing awareness of data privacy and security
concerns has led to the development of secure data-sharing platforms and
protocols. Ensuring the confidentiality and integrity of patient data is
essential for biomarker research and adoption.
In today's fast-paced world, Neurological disorders
can have debilitating effects on individuals and society as a whole. In a
fast-paced world, where every moment counts, early diagnosis is essential.
Neurological biomarkers allow for the identification of subtle neurological
changes before overt symptoms manifest. This early detection enables timely
intervention, potentially preventing disease progression and minimizing the
impact on a person's quality of life. The concept of precision medicine,
tailored to an individual's unique biological characteristics, is gaining
prominence. Neurological biomarkers provide the foundation for personalized
treatment plans. In a world where one size doesn't fit all, these biomarkers
guide healthcare providers in selecting the most suitable therapies, optimizing
treatment outcomes, and minimizing adverse effects. The fast-paced nature of
drug development demands efficient screening of potential treatments.
Neurological biomarkers play a pivotal role in expediting drug development by
serving as surrogate endpoints in clinical trials. They allow researchers to
monitor treatment responses more rapidly and accurately, reducing the time and
resources required to bring new therapies to market. With busy lifestyles,
individuals and healthcare providers need objective tools to monitor disease
progression. Neurological biomarkers offer quantifiable and objective data,
enabling continuous monitoring without the need for frequent clinical visits.
This empowers patients to take charge of their health and minimizes disruptions
to their daily routines. In the fast-paced world of scientific research,
neurological biomarkers provide researchers with a deeper understanding of
disease mechanisms. This accelerates the pace of discoveries and breakthroughs
in neurology, leading to the development of innovative treatments and
diagnostic tools.
The growing awareness among consumers regarding health
and wellness has shifted the focus towards the ideology of "prevention is
better than cure." As a result, more individuals are relying on
nutraceuticals, functional foods, and dietary and Neurological Biomarkers to
lead a healthy and disease-free life.
In recent times, Neurological biomarkers have become
instrumental in identifying subtle neurological changes before the onset of
clinical symptoms. This early detection allows for timely intervention and the
initiation of treatment strategies, potentially slowing disease progression and
improving patient outcomes. Recent times have witnessed a shift towards
personalized medicine, where treatment approaches are tailored to individual
patients. Neurological biomarkers serve as the cornerstone of personalized care
by enabling healthcare providers to select the most appropriate therapies based
on a patient's unique biomarker profile. This approach minimizes the risk of
adverse effects and optimizes treatment efficacy. In the fast-paced world of
scientific research, neurological biomarkers have facilitated a deeper
understanding of the intricate mechanisms underlying neurological disorders.
Researchers use these biomarkers to track disease progression, study therapeutic
targets, and assess the effectiveness of experimental treatments. This
accelerated pace of research has yielded promising discoveries and innovative
solutions. However, the Complexity of Neurological Disorders may hinder market
growth. Moreover, challenges related to Stringent Validation Requirements and Data
Privacy and Security Concerns may pose obstacles to the Neurological Biomarkers
market in the near future.
The Global Neurological Biomarkers Market is segmented
into type, application, end-user, regional distribution, and company
Based on its formulation, the Imaging biomarkers, as
the name suggests, are primarily focused on visualizing and mapping the nervous
system's structure and function. Techniques such as magnetic resonance imaging
(MRI), computed tomography (CT), positron emission tomography (PET), and
single-photon emission computed tomography (SPECT) allow healthcare
professionals and researchers to non-invasively observe the brain's anatomy,
blood flow, metabolic activity, and connectivity. Imaging biomarkers offer
comprehensive diagnostic capabilities, which are crucial for neurological
disorders. They enable the detection of abnormalities, lesions, or structural
changes in the brain or nervous system. This is especially vital in the diagnosis
of conditions like brain tumors, strokes, and traumatic brain injuries, where
accurate visualization is imperative for timely intervention. The ability to
monitor disease progression is another key strength of imaging biomarkers.
Neurological disorders often evolve over time, and longitudinal imaging studies
allow healthcare providers to track changes in the nervous system.
Based on region, North America segment is expected to
grow during the forecast period. North America boasts a highly
developed healthcare infrastructure, with state-of-the-art hospitals, research
centers, and diagnostic laboratories. This infrastructure facilitates the
extensive utilization of neurological biomarkers in clinical practice,
research, and drug development. The region is a global leader in neurological
research and innovation. Renowned academic institutions, such as Harvard, Johns
Hopkins, and the Mayo Clinic, continuously contribute to groundbreaking
research in neurology. These institutions drive the development and adoption of
neurological biomarkers. North America has a relatively high prevalence of
neurological disorders, including Alzheimer's disease, Parkinson's disease, and
multiple sclerosis. The rising aging population contributes to the increased
incidence of these conditions, creating a strong demand for biomarkers for
early diagnosis and management.
The Asia-Pacific market is poised to be the
fastest-growing market, offering lucrative growth opportunities for
Neurological Biomarkers players during the forecast period. Factors such as
Many countries in the Asia-Pacific region are experiencing significant
increases in healthcare expenditure. As a result, there is greater investment
in healthcare infrastructure, research, and advanced diagnostic technologies,
creating a conducive environment for biomarker adoption. Similar to North
America, the Asia-Pacific region is also facing a demographic shift with a
growing aging population. This demographic change is associated with an
increased prevalence of neurological disorders, driving the demand for
biomarkers. Emerging economies within the Asia-Pacific region, such as China
and India, are witnessing rapid economic growth and urbanization. This growth
is accompanied by improved access to healthcare services and increased
awareness of neurological health.
Major companies operating in Global Neurological
Biomarkers Market are:
- PERKINELMER INC.
- Abbott Laboratories Inc
- Thermo Fisher Scientific, Inc.
- Banyan Biomarkers, Inc.
- Bio-Rad Laboratories, Inc.
- F. HOFFMANN-LA ROCHE LTD.
- Merck & Co., Inc.
- DiaGenic ASA
- Johnson & Johnson Services, Inc.
- Myriad Genetics, Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The Advancements in Diagnostic Technologies and Increased
investment in neurological biomarker research and development by pharmaceutical
companies are key drivers of the Neurological Biomarkers market. In recent
years, the growing shift toward personalized medicine approaches emphasizes the
importance of biomarkers in tailoring treatment plans to individual patients.
Biomarkers enable the identification of patient-specific profiles, optimizing
therapeutic outcomes and reducing adverse effects. Moreover, the growing
consumer emphasis on preventative healthcare products has enhanced production
and marketing efforts. To meet the demands of the market, manufacturers are
increasingly incorporating cutting-edge technologies with high production
efficiency. Rising consumer acceptance and continuous product innovation will
further ensure the growth of the Neurological Biomarkers and supplements market
in the coming years.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Neurological Biomarkers Market – Global
Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 Segmented
By Type (Imaging, Proteomic, Genomic, Metabolomic, Others), By Application
(Multiple Sclerosis, Alzheimer's Disease, Autism Spectrum Disorder, Parkinson's
Disease, Others), By End-User (Research Organizations, Hospital & Hospital
Laboratories, Independent Clinical Diagnostic Centers, Others), By Region &
Competition”, has evaluated the future growth potential of Global Neurological
Biomarkers Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Neurological
Biomarkers Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com